YAP1 mediates resistance to MEK1/2 inhibition in neuroblastomas with hyperactivated RAS signalling

Relapsed neuroblastomas are enriched with activating mutations of the RAS-MAPK signaling pathway. The MEK1/2 inhibitor trametinib delays tumor growth but does not sustain regression in neuroblastoma preclinical models. Recent studies have implicated the Hippo pathway transcriptional coactivator prot...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Coggins, Grace E., Farrel, Alvin, Rathi, Komal S., Hayes, Colin M., Scolaro, Laura, Rokita, Jo Lynne, Maris, John M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6911631/
https://ncbi.nlm.nih.gov/pubmed/31672841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-1415
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi